TW202340478A - 用於鼻咽癌診斷的試劑和方法 - Google Patents
用於鼻咽癌診斷的試劑和方法 Download PDFInfo
- Publication number
- TW202340478A TW202340478A TW111140513A TW111140513A TW202340478A TW 202340478 A TW202340478 A TW 202340478A TW 111140513 A TW111140513 A TW 111140513A TW 111140513 A TW111140513 A TW 111140513A TW 202340478 A TW202340478 A TW 202340478A
- Authority
- TW
- Taiwan
- Prior art keywords
- content
- solution
- mirna
- nasopharyngeal
- mir
- Prior art date
Links
- 206010061306 Nasopharyngeal cancer Diseases 0.000 title claims abstract description 167
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 title claims description 134
- 239000000104 diagnostic biomarker Substances 0.000 title 1
- 230000011987 methylation Effects 0.000 claims abstract description 165
- 238000007069 methylation reaction Methods 0.000 claims abstract description 165
- 238000001514 detection method Methods 0.000 claims abstract description 163
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 139
- 241000700605 Viruses Species 0.000 claims abstract description 100
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims abstract description 34
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims abstract description 34
- 238000012360 testing method Methods 0.000 claims abstract description 28
- 238000003745 diagnosis Methods 0.000 claims abstract description 26
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 5
- 239000000523 sample Substances 0.000 claims description 245
- 239000002679 microRNA Substances 0.000 claims description 224
- 108020004414 DNA Proteins 0.000 claims description 223
- 239000000243 solution Substances 0.000 claims description 222
- 108091070501 miRNA Proteins 0.000 claims description 218
- 238000000034 method Methods 0.000 claims description 190
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 175
- 239000003761 preservation solution Substances 0.000 claims description 148
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 142
- 238000004321 preservation Methods 0.000 claims description 142
- 108020004707 nucleic acids Proteins 0.000 claims description 118
- 150000007523 nucleic acids Chemical class 0.000 claims description 118
- 102000039446 nucleic acids Human genes 0.000 claims description 118
- 239000007788 liquid Substances 0.000 claims description 115
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 108
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 99
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 claims description 96
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 89
- 238000000605 extraction Methods 0.000 claims description 78
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 78
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 74
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 71
- 239000011780 sodium chloride Substances 0.000 claims description 71
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 70
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 67
- 239000000463 material Substances 0.000 claims description 65
- 230000009089 cytolysis Effects 0.000 claims description 64
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 62
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 61
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 61
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 claims description 59
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 58
- 238000001179 sorption measurement Methods 0.000 claims description 48
- 239000011324 bead Substances 0.000 claims description 41
- 108010024636 Glutathione Proteins 0.000 claims description 39
- 239000007983 Tris buffer Substances 0.000 claims description 39
- 229960003180 glutathione Drugs 0.000 claims description 39
- 239000001509 sodium citrate Substances 0.000 claims description 39
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 39
- -1 NP40 Chemical compound 0.000 claims description 37
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 37
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 37
- 239000001488 sodium phosphate Substances 0.000 claims description 36
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 36
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 36
- 235000019801 trisodium phosphate Nutrition 0.000 claims description 36
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 35
- 230000003612 virological effect Effects 0.000 claims description 34
- 108700042652 LMP-2 Proteins 0.000 claims description 32
- 230000007067 DNA methylation Effects 0.000 claims description 30
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 29
- 235000011147 magnesium chloride Nutrition 0.000 claims description 29
- 108091033415 Epstein Barr virus miR-BART1 stem-loop Proteins 0.000 claims description 28
- 108091060434 Epstein Barr virus miR-BART7 stem-loop Proteins 0.000 claims description 28
- 238000012216 screening Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000004140 cleaning Methods 0.000 claims description 21
- 108091060425 Epstein Barr virus miR-BART13 stem-loop Proteins 0.000 claims description 18
- 108091027124 Epstein Barr virus miR-BART17 stem-loop Proteins 0.000 claims description 18
- 108091033419 Epstein Barr virus miR-BART2 stem-loop Proteins 0.000 claims description 18
- 108091060433 Epstein Barr virus miR-BART6 stem-loop Proteins 0.000 claims description 18
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 238000001959 radiotherapy Methods 0.000 claims description 14
- 238000002659 cell therapy Methods 0.000 claims description 13
- 239000003242 anti bacterial agent Substances 0.000 claims description 12
- 229940088710 antibiotic agent Drugs 0.000 claims description 12
- 239000003480 eluent Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 11
- 244000309459 oncolytic virus Species 0.000 claims description 11
- 238000001356 surgical procedure Methods 0.000 claims description 11
- 108010067770 Endopeptidase K Proteins 0.000 claims description 10
- 230000008685 targeting Effects 0.000 claims description 9
- 239000012472 biological sample Substances 0.000 claims description 8
- 229960005322 streptomycin Drugs 0.000 claims description 8
- 239000013068 control sample Substances 0.000 claims description 7
- 230000001909 effect on DNA Effects 0.000 claims description 7
- 229960004887 ferric hydroxide Drugs 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 239000003463 adsorbent Substances 0.000 claims description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims description 6
- 230000009977 dual effect Effects 0.000 claims description 5
- 239000012487 rinsing solution Substances 0.000 claims description 3
- 239000001226 triphosphate Substances 0.000 claims description 2
- 235000011178 triphosphate Nutrition 0.000 claims description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 150000003385 sodium Chemical class 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 24
- 239000003550 marker Substances 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 2
- 229920002477 rna polymer Polymers 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 description 82
- 238000010839 reverse transcription Methods 0.000 description 36
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 26
- 238000005070 sampling Methods 0.000 description 20
- 108091037727 virus miR-BART1 stem-loop Proteins 0.000 description 17
- 108091058685 virus miR-BART7 stem-loop Proteins 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- 230000001680 brushing effect Effects 0.000 description 14
- 210000001989 nasopharynx Anatomy 0.000 description 14
- 108091087008 virus miR-BART13 stem-loop Proteins 0.000 description 13
- 108091026038 virus miR-BART2 stem-loop Proteins 0.000 description 13
- 230000003321 amplification Effects 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000002096 quantum dot Substances 0.000 description 12
- 108091064124 virus miR-BART17 stem-loop Proteins 0.000 description 12
- 108091057061 virus miR-BART6 stem-loop Proteins 0.000 description 12
- 238000002123 RNA extraction Methods 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000001574 biopsy Methods 0.000 description 10
- 239000012139 lysis buffer Substances 0.000 description 10
- 108091027943 miR-16 stem-loop Proteins 0.000 description 10
- 108091074057 miR-16-1 stem-loop Proteins 0.000 description 10
- 108091056204 miR-16-2 stem-loop Proteins 0.000 description 10
- 238000003753 real-time PCR Methods 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 108700011259 MicroRNAs Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 238000003359 percent control normalization Methods 0.000 description 8
- 239000002699 waste material Substances 0.000 description 8
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 108700039887 Essential Genes Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 230000000171 quenching effect Effects 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 6
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 6
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 5
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000012148 binding buffer Substances 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- 108010077895 Sarcosine Proteins 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 3
- 238000001190 Q-PCR Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 229940043230 sarcosine Drugs 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 108091029430 CpG site Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- 101710192602 Latent membrane protein 1 Proteins 0.000 description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- BMYCCWYAFNPAQC-UHFFFAOYSA-N 2-[dodecyl(methyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCN(C)CC(O)=O BMYCCWYAFNPAQC-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010073324 Keratinising squamous cell carcinoma of nasopharynx Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010073328 Undifferentiated nasopharyngeal carcinoma Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- ZZTURJAZCMUWEP-UHFFFAOYSA-N diaminomethylideneazanium;hydrogen sulfate Chemical compound NC(N)=N.OS(O)(=O)=O ZZTURJAZCMUWEP-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002681 effect on RNA Effects 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000007886 magnetic bead extraction Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000015386 nasopharyngeal disease Diseases 0.000 description 1
- 208000028133 nasopharyngeal squamous cell carcinoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002661 proton therapy Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229940048098 sodium sarcosinate Drugs 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- BRPNNYXZQLLLSN-UHFFFAOYSA-N sodium;dodecane Chemical compound [Na+].CCCCCCCCCCC[CH2-] BRPNNYXZQLLLSN-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000035295 susceptibility to 1 nasopharyngeal carcinoma Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- VVXLCVDMXPHUAA-UKVIHGRNSA-K trisodium (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O VVXLCVDMXPHUAA-UKVIHGRNSA-K 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111251797 | 2021-10-25 | ||
| CN202111251797.9 | 2021-10-25 | ||
| CN202211272683.7A CN115521996A (zh) | 2021-10-25 | 2022-10-18 | 用于鼻咽癌诊断的试剂和方法 |
| CN202211272683.7 | 2022-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202340478A true TW202340478A (zh) | 2023-10-16 |
Family
ID=84703373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111140513A TW202340478A (zh) | 2021-10-25 | 2022-10-25 | 用於鼻咽癌診斷的試劑和方法 |
Country Status (3)
| Country | Link |
|---|---|
| CN (2) | CN115521996A (fr) |
| TW (1) | TW202340478A (fr) |
| WO (1) | WO2023072076A1 (fr) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009033185A1 (fr) * | 2007-09-06 | 2009-03-12 | University Of Massachusetts | SIGNATURES D'ARNmi SPÉCIFIQUE À UN VIRUS DESTINÉES AU DIAGNOSTIC ET AUX TRAITEMENT D'INFECTIONS VIRALES |
| CN102268477A (zh) * | 2011-06-15 | 2011-12-07 | 中山大学肿瘤防治中心 | 一种与鼻咽癌相关的EB病毒miRNA的应用 |
| US20140235484A1 (en) * | 2013-02-19 | 2014-08-21 | The Johns Hopkins University | Methods for detection and differentiation of origin of viral dna |
| CN107075568A (zh) * | 2014-05-01 | 2017-08-18 | 阿姆斯特丹自由大学医学中心基金会 | 作为生物标记物的小ncRNA |
| WO2017105353A1 (fr) * | 2015-12-18 | 2017-06-22 | Agency For Science, Technology And Research | Détection et quantification d'une séquence d'acide nucléique d'un micro-organisme |
| CN106755590A (zh) * | 2017-01-22 | 2017-05-31 | 中南大学湘雅医院 | 一种用于检测传单患者eb病毒fish检测探针 |
| CN111902545B (zh) * | 2019-01-03 | 2024-09-06 | 杭州诺辉健康科技有限公司 | 尿液样本保存及dna提取的组合物及方法 |
| CN110079603A (zh) * | 2019-06-14 | 2019-08-02 | 福建省肿瘤医院（福建省肿瘤研究所、福建省癌症防治中心） | 一种鼻咽癌标志物的检测引物、探针及其应用 |
| CN114457192B (zh) * | 2021-07-07 | 2023-02-07 | 中山大学 | 对唾液中EB病毒CpG位点进行甲基化分型的试剂在制备鼻咽癌诊断试剂盒中的应用 |
-
2022
- 2022-10-18 CN CN202211272683.7A patent/CN115521996A/zh active Pending
- 2022-10-25 TW TW111140513A patent/TW202340478A/zh unknown
- 2022-10-25 WO PCT/CN2022/127393 patent/WO2023072076A1/fr unknown
- 2022-10-25 CN CN202280071246.0A patent/CN118510895A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115521996A (zh) | 2022-12-27 |
| WO2023072076A1 (fr) | 2023-05-04 |
| CN118510895A (zh) | 2024-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110904225B (zh) | 用于肝癌检测的组合标志物及其应用 | |
| CN107636172B (zh) | 用于诊断、预测或监测肺孢子菌肺炎的工具 | |
| CN110387421A (zh) | 用于肺癌检测的DNA甲基化qPCR试剂盒及使用方法 | |
| WO2021223349A1 (fr) | Séquence de protection, amorce, sonde, composition et kit pour la détection rapide en régime permanent du nouveau coronavirus, leur utilisation et procédé correspondant | |
| CN109504780B (zh) | 用于肺癌检测的DNA甲基化qPCR试剂盒及使用方法 | |
| WO2021004215A1 (fr) | Réactif de détection combiné multigénique | |
| CN109371133B (zh) | 一组与胰腺癌相关的LncRNA分子标记物及其应用 | |
| AU2020310247B2 (en) | Gene marker combination and use thereof | |
| WO2017054325A1 (fr) | Marqueurs de diagnostic du cancer du sein combiné à un nécessaire de détection | |
| JP2017500894A (ja) | 川崎病の迅速診断用核酸マーカー及びそのキット | |
| CN110964823A (zh) | 用于结直肠癌检测的dna甲基化试剂盒和检测方法 | |
| CN114774540A (zh) | 包括外泌体miR-106b-3p、miR-330-5p等在肺癌诊断中的应用 | |
| CN108866187B (zh) | 一种与肺癌辅助诊断相关的长链非编码rna标志物及其应用 | |
| TWI815043B (zh) | 腫瘤檢測試劑及試劑盒 | |
| TWI815044B (zh) | 肺癌檢測試劑及試劑盒 | |
| TWI385252B (zh) | 一種癌症篩檢的方法 | |
| CN115627297B (zh) | 一种检测人粪便幽门螺旋杆菌核酸的试剂盒 | |
| CN109735612B (zh) | 川崎病冠状动脉瘤并发症的生物分子标志物及其试剂盒 | |
| CN111455094A (zh) | 检测深部感染真菌的组合物、试剂盒、用途及其方法 | |
| TW202340478A (zh) | 用於鼻咽癌診斷的試劑和方法 | |
| CN108913762A (zh) | 用于检测慢性鼻窦炎伴鼻息肉亚型的试剂盒及cst1基因作为生物标志物的应用 | |
| WO2017167034A1 (fr) | Procédé et trousse de détection du cancer de la vessie | |
| CN111733226B (zh) | 一种检测克罗恩病的环状rna标志物及应用 | |
| CN114410795A (zh) | 基于miRNA特征标记的肝癌早期检测 | |
| CN108949954A (zh) | 用于检测慢性鼻窦炎伴鼻息肉亚型的试剂盒及alox15基因作为生物标志物的应用 |